This study was conducted to characterize the metabolism and pharmacokinetic properties of NEO 212 in preclinical models. NEO 212, a conjugate of Temozolomide (TMZ) and Perillyl Alcohol (POH), has been shown to provide a method of providing chemotherapeutic treatment of brain-based-glioblastomas than the current TMZ-only therapy courses alone. In the study, NeOnc Technologies used mass […]